Immuno-polymeric drugs for prostate cancer therapy

点击翻译按钮获取中文摘要

Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.